Core Viewpoint - Sichuan Huiyu Pharmaceutical Co., Ltd. has received the drug registration certificate for injectable methotrexate hydrochloride, which is expected to enhance its competitive position in the market [1][4]. Drug Information - Injectable methotrexate hydrochloride is a cytotoxic alkylating agent effective against both resting and rapidly dividing tumor cells, particularly used for high-dose pre-treatment before hematopoietic stem cell transplantation in multiple myeloma patients [1][2]. - The drug is classified as a Category 4 chemical drug and has passed the consistency evaluation for generic drug quality and efficacy [4]. Market Context - The original manufacturer, Acrotech Biopharma Inc., has already launched injectable methotrexate hydrochloride in China, with Xian Libang holding the approval for the drug [2]. - According to data from Minet, the sales revenue of injectable methotrexate hydrochloride in urban public hospitals in China was approximately 86 million yuan in the first half of 2024 [3]. Company Impact - The approval of injectable methotrexate hydrochloride is expected to provide greater support in areas such as medical insurance payments and procurement by medical institutions due to its passing of the consistency evaluation [4]. - The company has initiated preparations for the product's market launch, although future revenue generation remains uncertain due to competition and market dynamics [4].